扶正化瘀方加味联合内分泌疗法治疗晚期前列腺癌临床研究-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

扶正化瘀方加味联合内分泌疗法治疗晚期前列腺癌临床研究

Clinical research on the treatment of advanced prostate cancer with modified Fuzheng Huayu Formula combined with endocrine therapy

ES评分 0 浏览量：72 下载量：0

全文阅读下载引用收藏

DOI	10.12208/j.ijcr.20250491
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(10)
作者	安宁, 何宏艳, 李玉静, 刘贺, 赵东杰,
作者单位	河北北方学院附属第二医院河北张家口
摘要	目的研究应用扶正化瘀方加味与内分泌疗法联合方案治疗晚期前列腺癌的临床疗效。方法选取70例2023年4月-2024年3月在我院接受治疗的晚期前列腺癌患者，按照患者入院先后顺序将70例患者平均分成两组，即对照组35例与观察组35例，两组均接受内分泌疗法，同时观察组添加扶正化瘀方加味治疗。研究对比两组治疗方案的最终疗效。结果治疗后观察组患者的血清前列腺特异抗原水平、游离前列腺特异性抗原、血管内皮生长因子低于对照组，且发生的用药不良反应少于对照组，最终取得的疾病控制有效率高于对照组，（P＜0.05）。结论晚期前列腺癌采取内分泌疗法同时加入扶正化瘀方加味治疗，可快速改善临床指标，提升疾病控制效果。
Abstract	Objective To study the clinical efficacy of the combined treatment of modified Fuzheng Huayu Formula and endocrine therapy for advanced prostate cancer. Methods A total of 70 patients with advanced prostate cancer who were treated in our hospital from April 2023 to March 2024 were selected. The 70 patients were evenly divided into two groups according to the order of admission, namely the control group (35 cases) and the observation group (35 cases). Both groups received endocrine therapy, and the observation group was treated with modified Fuzheng Huayu Formula. The final therapeutic effects of the two groups of treatment plans were studied and compared. Results After treatment, the levels of serum prostate-specific antigen, free prostate-specific antigen, and vascular endothelial growth factor in the observation group were lower than those in the control group, and the incidence of adverse drug reactions was less than that in the control group. The final disease control effectiveness rate was higher than that in the control group, (P < 0.05). Conclusion For advanced prostate cancer, the treatment of endocrine therapy combined with the modified Fuzheng Huayu Formula can rapidly improve clinical indicators and enhance the disease control effect.
关键词	扶正化瘀方；内分泌疗法；晚期前列腺癌；临床疗效
KeyWord	Fuzheng Huayu formula; Endocrine therapy; Advanced prostate cancer; Clinical efficacy
基金项目
页码	109-111

参考文献
相关文献

[1] 李其鹏,陈铭梅,周松河,等.蜂针疗法联合内分泌疗法治疗晚期前列腺癌患者的疗效观察
[J].大医生,2024, 9(14): 80-82.

[2] 刘凡,张永标,贾守法.PKRP术联合内分泌疗法治疗晚期前列腺癌合并膀胱出口梗阻的短期疗效分析
[J].医学食疗与健康,2022,20(8):47-49,68.

[3] 赵硕,姚明,杨鹏,等.苗药酢浆草组方联合内分泌疗法治疗晚期前列腺癌疗效观察
[J].现代中西医结合杂志,2022, 31(24):3452-3455,3471.

[4] 李文骥,胡芳,徐魏.川龙抑癌汤治疗前列腺癌的作用机制探讨
[J].实用临床医药杂志,2022,26(5):18-23,29.

[5] 李亮亮,孙文国.经尿道前列腺电切术联合内分泌去势疗法治疗晚期前列腺癌的临床效果
[J].临床医学研究与实践,2021,6(33):46-48.

[6] 周俊,陈如,马锋.经尿道前列腺等离子电切术联合内分泌疗法治疗晚期前列腺癌合并膀胱出口梗阻的临床疗效观察
[J].国际泌尿系统杂志,2020,40(2):239-242.

[7] 齐涛,黄世高,高红祥,等.放疗联合内分泌治疗晚期复发性前列腺癌
[J].西部医学,2020,32(9):1324-1327.

[8] 卫圣男,陆安琪.晚期前列腺癌内分泌治疗的临床干预效果
[J].世界临床药物,2024,45(9):1004.

[9] 刘和洋,红华,刘倩,等.前列腺癌新辅助内分泌治疗疗效评估的影像学进展
[J].生物医学工程与临床,2024,28(5): 742-747.

引用本文

安宁, 何宏艳, 李玉静, 刘贺, 赵东杰. 扶正化瘀方加味联合内分泌疗法治疗晚期前列腺癌临床研究 [J]. 国际临床研究杂志. 2025; 9; (10). 109 - 111.

文献评论

相关学者

相关机构